Autologous vs. Allogeneic Cells

Using a patient’s own cells eliminates compatibility concerns because mitochondrial and nuclear DNA match. The article argues that VSELs address the concern that autologous cells are too old by maintaining youthful cellular characteristics regardless of patient age. The article says FDA enforcement largely shut down the U.S. umbilical cord stem cell industry. Even premium international settings are described as having inherently difficult quality control because of supply-chain complexity. Allogeneic umbilical cord supply chains introduce risks related to donors, pathogen testing, processing, storage, shipping, viability, and contamination. Umbilical cord stem cells remain commonly used outside the United States.